Collections Clopidogrel in ACS

Clopidogrel in ACS

Questioning Medicine upcoming podcast #FOAMed #MedQuestioning
Jing Liang, Zhijian Wang, Dongmei Shi, Yuyang Liu, Yingxin Zhao, Hongya Han, Yueping Li, Wei Liu, Linlin Zhang, Lixia Yang, Yujie Zhou
We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled. Maximal platelet aggregation (MPA) was assessed before, 24 hours, and 30 days after a 300-mg loading dose of clopidogrel prior to PCI. After PCI, 370 patients with CR were randomized to receive clopidogrel 75 mg/d (n = 184) or 150 mg/d (n = 186) for 30 days...
April 2015: Angiology
Aaron J Peace, Fabio Mangiacapra, Els Bailleul, Leen Delrue, Karen Dierickx, Micaela Conte, Etienne Puymirat, Anne Lies Fraeymans, Pieter Meeus, Jozef Bartunek, Massimo Volpe, Emanuele Barbato
OBJECTIVE: Platelet α2A-adrenergic receptors (ARs) mediate platelet aggregation in response to sympathetic stimulation. The 6.3-kb variant of α2A-AR gene is associated with increased epinephrine-induced platelet aggregation in healthy volunteers. The cytochrome P450 2C19*2 (CYP2C19*2) loss-of-function allele influences P2Y12-mediated platelet inhibition and hence the rate of major adverse cardiovascular events. We assessed the influence of 6.3-kb α2A-AR gene variant on platelet aggregation and its interaction with CYP2C19*2 loss-of-function allele in patients with stable angina on aspirin and clopidogrel (dual antiplatelet therapy)...
June 2014: Arteriosclerosis, Thrombosis, and Vascular Biology
Ivano Bonadei, Edoardo Sciatti, Enrico Vizzardi, Antonio D'Aloia, Riccardo Raddino, Marco Metra
The activation and aggregation of platelets at sites of vascular injury or near to implanted stent are pivotal in the development of thrombotic events during and after an acute coronary syndrome (ACS) or a percutaneous coronary intervention (PCI). For that reason, an exclusively oral dual antiplatelet treatment regimen with platelet P2Y12 receptor antagonists in addition to the cyclooxygenase inhibitor aspirin has become the cornerstone of treatment in that contest. However, every trial underlines the same problem: if maximizing antiplatelet therapy significantly attenuates ischemic events in patients with coronary artery disease, on the other side it may also increase bleeding phenomena...
2014: Recent Patents on Cardiovascular Drug Discovery
Tracy Y Wang, David J Magid, Henry H Ting, Shuang Li, Karen P Alexander, Matthew T Roe, Eric D Peterson
BACKGROUND: Timely and appropriate use of antiplatelet and anticoagulant therapies has been shown to improve outcomes among ST-segment elevation myocardial infarction (STEMI) patients but has not been well described in patients transferred for primary percutaneous coronary intervention (PCI). METHODS: We examined 16,801 (26%) transfer and 47,329 direct-arrival STEMI patients treated with primary PCI at 441 Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines hospitals...
June 2014: American Heart Journal
Nikolai Juul, Gunnar Gislason, Jonas Bjerring Olesen, Morten Lamberts, Morten Lock Hansen, Deniz Karasoy, Christine Benn Christiansen, Christian Torp-Pedersen, Rikke Sorensen
BACKGROUND: Dual anti-platelet treatment with clopidogrel and aspirin is indicated for most patients after myocardial infarction. We examined the risk/benefit relationship of dual anti-platelet treatment according to age in a nationwide cohort of 30,532 myocardial infarction patients without revascularization. METHODS: Patients admitted with first-time myocardial infarction in 2002-2010, not undergoing revascularization, were identified from nationwide Danish registers...
September 2017: European Heart Journal. Acute Cardiovascular Care
Joshua P Loh, Rebecca Torguson, Lakshmana K Pendyala, Alfazir Omar, Fang Chen, Lowell F Satler, Augusto D Pichard, Ron Waksman
Premature antiplatelet therapy discontinuation (ATD) after drug-eluting stent (DES) implantation is known to predict stent thrombosis (ST). However, recent data suggest that a shorter antiplatelet therapy duration is safe with newer generation DESs. The study aimed to compare the impact of early and late clopidogrel ATDs on ST in a real-world registry of first- and second-generation DES use. A total of 6,236 patients who underwent DES implantation were analyzed retrospectively: 4,217 received first-generation DESs (sirolimus- and paclitaxel-eluting stents) and 2,019 received second-generation DESs (everolimus-eluting stents)...
June 15, 2014: American Journal of Cardiology
Qing Wang, Rickard Ljung, Jesper Lagergren, Yunxia Lu
BACKGROUND: It is unclear whether concomitant use of clopidogrel and proton-pump inhibitors (PPIs) increases the risk of recurrence of cardiovascular disease or death in patients at high risk of upper gastrointestinal (GI) bleeding. METHODS: Based on the Swedish Patient Register, a cohort of cardiovascular disease (including acute myocardial infarction, stroke and angina, from 2006 to 2008) was selected from a population with any diagnosis of upper GI bleeding. Data on drug prescription was retrieved from the Prescribed Drug Register...
April 15, 2014: BMC Pharmacology & Toxicology
Payal Kohli, Lars Wallentin, Eric Reyes, Jay Horrow, Steen Husted, Dominick J Angiolillo, Diego Ardissino, Gerald Maurer, Joao Morais, José C Nicolau, Ali Oto, Robert F Storey, Stefan K James, Christopher P Cannon
BACKGROUND: We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (e.g., cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events. METHODS AND RESULTS: In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291)...
February 12, 2013: Circulation
Peter K Smith, Lawrence T Goodnough, Jerrold H Levy, Robert S Poston, Mary A Short, Govinda J Weerakkody, Leroy A Lenarz
OBJECTIVES: The objective of this study was to characterize the bleeding, transfusion, and other outcomes of patients related to the timing of prasugrel or clopidogrel withdrawal before coronary artery bypass grafting (CABG). BACKGROUND: There is little evidence to guide clinical decision making regarding the use of prasugrel in patients who may need urgent or emergency CABG. Experience with performing CABG in the presence of clopidogrel has raised concern about perioperative bleeding complications that are unresolved...
July 31, 2012: Journal of the American College of Cardiology
Shaun G Goodman, Robert Clare, Karen S Pieper, José C Nicolau, Robert F Storey, Warren J Cantor, Kenneth W Mahaffey, Dominick J Angiolillo, Steen Husted, Christopher P Cannon, Stefan K James, Jan Kilhamn, P Gabriel Steg, Robert A Harrington, Lars Wallentin
BACKGROUND: The clinical significance of the interaction between clopidogrel and proton pump inhibitors (PPIs) remains unclear. METHODS AND RESULTS: We examined the relationship between PPI use and 1-year cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in patients with acute coronary syndrome randomized to clopidogrel or ticagrelor in a prespecified, nonrandomized subgroup analysis of the Platelet Inhibition and Patient Outcomes (PLATO) trial...
February 28, 2012: Circulation
Z M Chen, L X Jiang, Y P Chen, J X Xie, H C Pan, R Peto, R Collins, L S Liu
BACKGROUND: Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear. METHODS: 45,852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n=22,961) or matching placebo (n=22,891) in addition to aspirin 162 mg daily...
November 5, 2005: Lancet
(no author information available yet)
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. METHODS: CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed...
November 16, 1996: Lancet
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.